There is a growing demand for new innovative technologies for use in “hard-to-transfect” cells, such as primary cells and stem cells. Transfection tools are used routinely by 51% of life scientists surveyed. This market segment was valued at $1 billion in 2011 and is predicted to grow to $1.9B by 2016. The objective of this study was the commercial development of lipid nanoparticle (LNP) reagents for the delivery of nucleic acids to turn off or turn on target genes in “hard-to-transfect” primary and stem cells in vitro and in vivo. The neuron LNP transfection product has been commercialized by Precision NanoSystems under the SUB9KITS™ franchise, marketed as the Neuro9™ kit. Precision has provided demo kits to over 50 key opinion leaders and has started to generate revenue through repeated sales to early customers.